Skip to content
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Pediatric Endocrinology · Fanconi Renotubular Syndrome 4

The Pancreas: From Low Blood Sugar to HNF4A-MODY

At a Glance

Fanconi renotubular syndrome 4 can affect insulin release in two stages: excess insulin may cause newborn hypoglycemia, while reduced insulin release later can lead to HNF4A-MODY. Regular glucose screening helps guide treatment as children grow.

The same genetic change that affects the kidneys in Fanconi Renotubular Syndrome 4 (FRTS4) also plays a critical role in how the body manages blood sugar. The HNF4A gene acts as a master regulator in the pancreas, helping to guide the development of beta cells—the specialized cells that produce insulin [1].

In people with FRTS4, the variant’s effects on insulin secretion change with age. It often causes the pancreas to produce too much insulin at birth, followed by a period of normal function, and can eventually lead to a specific form of diabetes where the pancreas produces too little insulin [2].

The Beginning: Too Much Insulin

The first pancreatic sign of FRTS4 often happens before birth. Because the HNF4A variant causes the fetal pancreas to overproduce insulin—which acts like a growth hormone in the womb—babies are often born with macrosomia (a high birth weight) [3].

Immediately after birth, this excess insulin can cause hyperinsulinemic hypoglycemia (dangerously low blood sugar) [4]. In the largest study of patients with this specific condition, 14 out of 21 babies experienced this newborn hypoglycemia [3]. While this often requires treatment with glucose or medications like diazoxide in the NICU, the overproduction of insulin typically fades within the first few months of life [5][2].

The Transition to HNF4A-MODY (MODY1)

After the newborn period, most children have normal blood sugar for several years. However, as the child grows—often entering adolescence—the pancreas may begin to struggle. This leads to HNF4A-MODY (MODY1), a form of monogenic diabetes [6].

In pediatric cohorts with HNF4A variants, the median age for developing this form of diabetes is approximately 11 years, though it can emerge in early adulthood [7][3].

How HNF4A-MODY Differs from Other Diabetes

It is common for HNF4A-MODY to be misdiagnosed as autoimmune Type 1 or typical Type 2 diabetes because the symptoms (like high blood sugar and thirst) look the same. However, the biology is very different:

  • Not Autoimmune: Unlike autoimmune Type 1 diabetes, HNF4A-MODY is not caused by the immune system attacking the pancreas. Patients with HNF4A-MODY will typically test negative for islet autoantibodies, although a person can coincidentally have another form of diabetes [8]. They also continue to produce some of their own insulin for much longer, which can be measured by a C-peptide blood test interpreted alongside glucose levels [9].
  • Not Insulin Resistance: Type 2 diabetes is usually driven by “insulin resistance,” where the body’s cells stop responding to insulin. In HNF4A-MODY, the cells generally respond well; the problem is simply a genetic defect in the pancreatic beta cells’ ability to release enough insulin when it is needed [8].

A Unique Treatment Response

Because the biology of HNF4A-MODY is unique, the treatment is often unique as well. Many patients with HNF4A-MODY are highly sensitive to a class of oral medications called sulfonylureas [10].

These medications work by “closing a gate” on the surface of the pancreatic cells, which forces them to release the insulin they have already made [11]. For many patients, these pills can provide excellent blood sugar control and may allow them to avoid the need for daily insulin injections for years [12][13].

However, because these patients are so sensitive to the medication, doctors must carefully monitor for the risk of low blood sugar (hypoglycemia) caused by the treatment itself [14]. You should have a clear, clinician-approved plan for managing hypoglycemia, checking glucose with a continuous glucose monitor (CGM) or fingersticks, and knowing what to do if you are sick or cannot eat. As the condition progresses over decades, some patients may eventually need to add insulin to their treatment plan to maintain healthy blood sugar levels [15]. Regular screening through childhood and adulthood is the key to catching this transition early.

Common questions in this guide

Why can FRTS4 cause low blood sugar in a newborn?
An HNF4A variant can make the fetal pancreas produce too much insulin. High insulin can contribute to high birth weight and cause hyperinsulinemic hypoglycemia after birth. This excess insulin production often decreases during the first months of life, although some babies need glucose or diazoxide under neonatal care.
Does newborn hypoglycemia from FRTS4 mean my child already has diabetes?
Not necessarily. In FRTS4, excess insulin often fades after birth, and many children have normal blood sugar for several years. HNF4A-MODY can develop later, often around adolescence, but the timing varies from person to person.
How is HNF4A-MODY different from type 1 or type 2 diabetes?
HNF4A-MODY is caused by an inherited change affecting insulin release from pancreatic beta cells. It is not usually caused by the immune system attacking the pancreas, as in type 1 diabetes, and it is not typically driven by insulin resistance, as in type 2 diabetes. Islet autoantibodies and C-peptide results can help clinicians assess the pattern.
Are sulfonylureas used to treat HNF4A-MODY?
Many people with HNF4A-MODY respond well to sulfonylureas because these medicines stimulate the pancreas to release insulin. They can sometimes delay the need for insulin injections, but the dose must be individualized because treatment-related low blood sugar can occur. Some people eventually need insulin as insulin production changes over time.
What tests can help clarify whether rising blood sugar is HNF4A-MODY?
Clinicians may check islet autoantibodies and C-peptide along with blood glucose. Negative autoantibodies and continued C-peptide production can support a nonautoimmune pattern, but results must be interpreted by a healthcare professional. The child's clinical history and the identified HNF4A variant are also important.
What should families monitor as a child with FRTS4 grows?
Regular blood sugar screening through childhood and adulthood can detect the transition from newborn hypoglycemia to later diabetes. Families should discuss monitoring with a clinician, watch for increased thirst or nighttime urination, and learn how to respond to low blood sugar or illness. Continuous glucose monitoring or fingerstick testing may be recommended for some patients.

Get notified when new evidence is published on Fanconi renotubular syndrome 4 with maturity-onset diabetes of the young.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (15)
  1. 1

    HNF4A Haploinsufficiency in MODY1 Abrogates Liver and Pancreas Differentiation from Patient-Derived Induced Pluripotent Stem Cells.

    Ng NHJ, Jasmen JB, Lim CS, et al.

    iScience 2019; (16()):192-205 doi:10.1016/j.isci.2019.05.032.

    PMID: 31195238
  2. 2

    Prolonged episodes of hypoglycaemia in HNF4A-MODY mutation carriers with IGT. Evidence of persistent hyperinsulinism into early adulthood.

    Bacon S, Kyithar MP, Condron EM, et al.

    Acta diabetologica 2016; (53(6)):965-972 doi:10.1007/s00592-016-0890-9.

    PMID: 27552834
  3. 3

    Phenotypic Spectrum of HNF4α-Associated Fanconi Renotubular Syndrome.

    Emma F, Böckenhauer D, Mallett AJ, et al.

    Kidney international reports 2026; (11(8)):106616 doi:10.1016/j.ekir.2026.106616.

    PMID: 42440446
  4. 4

    Detection of hepatocyte nuclear factor 4A(HNF4A) gene variant as the cause for congenital hyperinsulinism leads to revision of the diagnosis of the mother.

    Vlachopapadopoulou EA, Dikaiakou E, Fotiadou A, et al.

    Journal of pediatric endocrinology & metabolism : JPEM 2021; (34(4)):527-530 doi:10.1515/jpem-2020-0302.

    PMID: 33031054
  5. 5

    Exceptional diazoxide sensitivity in hyperinsulinaemic hypoglycaemia due to a novel HNF4A mutation.

    Arya VB, Kalitsi J, Hickey A, et al.

    Endocrinology, diabetes & metabolism case reports 2019; (2019()).

    PMID: 31096182
  6. 6

    Heterozygous recurrent HNF4A variant p.Arg85Trp causes Fanconi renotubular syndrome 4 with maturity onset diabetes of the young, an autosomal dominant phenocopy of Fanconi Bickel syndrome with colobomas.

    Sheppard SE, Barrett B, Muraresku C, et al.

    American journal of medical genetics. Part A 2021; (185(2)):566-570 doi:10.1002/ajmg.a.61978.

    PMID: 33251707
  7. 7

    Clinical and genetic heterogeneity of HNF4A/HNF1A mutations in a multicentre paediatric cohort with hyperinsulinaemic hypoglycaemia.

    McGlacken-Byrne SM, Mohammad JK, Conlon N, et al.

    European journal of endocrinology 2022; (186(4)):417-427 doi:10.1530/EJE-21-0897.

    PMID: 35089870
  8. 8

    Monogenic diabetes: An evidence-based clinical approach.

    Bhattacharya S, Fernandez CJ, Kamrul-Hasan ABM, Pappachan JM

    World journal of diabetes 2025; (16(5)):104787 doi:10.4239/wjd.v16.i5.104787.

    PMID: 40487603
  9. 9

    Frequency and Characteristics of MODY 1 (HNF4A Mutation) and MODY 5 (HNF1B Mutation): Analysis From the DPV Database.

    Warncke K, Kummer S, Raile K, et al.

    The Journal of clinical endocrinology and metabolism 2019; (104(3)):845-855 doi:10.1210/jc.2018-01696.

    PMID: 30535056
  10. 10

    Treatment Options for Patients with Maturity-Onset Diabetes of the Young (MODY): A Systematic Review of Literature: 2026 Update.

    Zagaroli L, Di Berardino A, Petragnano F, et al.

    Diabetes therapy : research, treatment and education of diabetes and related disorders 2026; (17(7)):959-983 doi:10.1007/s13300-026-01884-2.

    PMID: 42295651
  11. 11

    Case Report: Beyond type 1 diabetes: a case of delayed MODY1 diagnosis and successful transition to sulfonylurea therapy.

    Gulisano C, Aloi C, Salina A, et al.

    Frontiers in medicine 2025; (12()):1590935 doi:10.3389/fmed.2025.1590935.

    PMID: 40486195
  12. 12

    MODY in Ukraine: genes, clinical phenotypes and treatment.

    Globa E, Zelinska N, Elblova L, et al.

    Journal of pediatric endocrinology & metabolism : JPEM 2017; (30(10)):1095-1103.

    PMID: 28862987
  13. 13

    Clinical characteristics, treatment, and treatment switch after molecular-genetic classification in individuals with maturity-onset diabetes of the young: Insights from the multicenter real-world DPV registry.

    Lanzinger S, Laubner K, Warncke K, et al.

    Journal of diabetes 2024; (16(11)):e70028 doi:10.1111/1753-0407.70028.

    PMID: 39511990
  14. 14

    A Case of Oral Semaglutide for Treatment of Hepatocyte Nuclear Factor 4A Maturity-Onset Diabetes of the Young.

    Grennan KN, Singh D, Chindris AM, Wilson JR

    AACE endocrinology and diabetes 2026; (13(2)):177-179 doi:10.1016/j.aed.2025.12.002.

    PMID: 41938282
  15. 15

    Novel Treatment Options in Patients with Maturity-Onset Diabetes of the Young.

    Müssig K

    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2025; (133(1)):51-58 doi:10.1055/a-2436-7723.

    PMID: 39379059

This page is for informational purposes only and does not constitute medical advice about Fanconi renotubular syndrome 4 or HNF4A-MODY. Discuss glucose monitoring, testing, and treatment with your child's healthcare team.